Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM, BSE: 507789) is a Gurugram, Haryana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹1,440 Cr, it ranks #1,407 by market cap among the 6,137 Indian listed companies on FinBizNet, and #22 of 63 in Pharmaceuticals. At ₹211.76 (as of 25 Oct 2026), the share price is 19.9% below its 52-week high of ₹264.50 and 36.6% above its 52-week low of ₹155.00. The share price is down 3.9% over one year and down 4.4% over three months.
| Current Price | ₹211.76 |
|---|---|
| Market Cap | ₹1,440 Cr |
| NSE Symbol | JAGSNPHARM |
| BSE Code | 507789 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 34.5 |
| Return on Equity | 16.69% |
| Return on Assets | 10.22% |
| 52-Week Range | ₹155.00 – ₹264.50 |
| 1-Year Price Change | -3.9% |
| 3-Month Price Change | -4.4% |
| Beta (1Y) | 0.22 |
| Dividend Yield | 1.15% |
| Headquarters | Gurugram, Haryana |
| Website | www.jagsonpal.com |
| Revenue | ₹82 Cr |
|---|---|
| Net Profit | ₹13 Cr |
| Net Margin | 16.0% |
| EPS (Basic) | ₹2.00 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.
1. Pharmaceuticals-This segment manufactures and sells pharmaceuticals and intermediate drugs.
1. Manufacturing and Trading of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Jagsonpal Pharmaceuticals Limited | ₹1,440 Cr | 34.5 | 16.69% | ₹82 Cr | -3.9% |
Listed by market capitalisation. Ratios are shown for context only.
Jagsonpal Pharmaceuticals Limited is trading at ₹211.76, with a market capitalisation of ₹1,440 Cr.
Jagsonpal Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Jagsonpal Pharmaceuticals Limited has a P/E of 34.5 and a return on equity of 16.69%.
Jagsonpal Pharmaceuticals Limited is listed on the NSE under the symbol JAGSNPHARM and on the BSE under the scrip code 507789.
Jagsonpal Pharmaceuticals Limited's share price is down 3.9% over one year and down 4.4% over three months. Its 52-week range is ₹155.00 to ₹264.50.
In Q1 FY27, Jagsonpal Pharmaceuticals Limited reported revenue of ₹82 Cr and net profit of ₹13 Cr, with basic EPS of ₹2 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.